Global Diagnostic Tests Market

Diagnostic Tests Comprehensive Study by Type (CBC, HGB/HCT, BMP, BUN Creatinine, Electrolyte Testing, HbA1c, CMP, Liver Panel, Renal Panel, Lipid Panel), Application (Central Laboratories, Primary Clinics), Disease Type (Hepatitis, HIV, HAI, HPV, TB, Influenza), Technology (Immunodiagnostics, PCR, NGS), Service Type (Assay, Kit & Reagent, Instruments) Players and Region - Global Market Outlook to 2030

Diagnostic Tests Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Snapshot:
Diagnostic tests are usually carried out in private or public laboratories equipped with suitable and sometimes expensive instruments and staffed with trained and qualified personnel to carry out the tests. The most common concern of governments in all nations affected by Covid-19 is the intolerable need to screen and test a large number of patients for possible Sars-Cov-2 infections. As a result, most of them face significant bottlenecks in the delivery of diagnostic kits for testing for the virus. Diagnostic virology companies are currently under immense pressure so as to provide reliable test kits, as well as demand in-vitro or point-of-care test capacities from the laboratories that are present in a variety of countries is increasing. The growth of this market is primarily because of the fact that there is an increasing global spread of infectious diseases, also the shift of focus from centralized laboratories to decentralized point-of-care tests, as well as the increased funding of the research into the diagnosis of infectious diseases.

Highlights from Diagnostic Tests Market Study
AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The key Players profiled in the report are Abbott Laboratories (United States), ARUP Laboratories (United States), OPKO Health, Inc. (United States), Bioscientia Institut für Medizinische Diagnostik GmbH (Germany), Charles River Laboratories (United States), Fresenius Medical Care (Germany), QIAGEN (Germany), NeoGenomics Laboratories, Inc. (United States), Genoptix, Inc. (United States), Healthscope Ltd. (Australia) and Labco (South Africa). Additionally, other players that are part of this comprehensive study are Laboratory Corporation of America Holdings (LabCorp) (United States), Quest Diagnostics (United States), Siemens Healthcare Private Limited (India) and Tulip Diagnostics (P) Ltd. (India).

Geographic Breakdown and Segment Analysis
The Global Diagnostic Tests market presents a comprehensive analysis of the Diagnostic Tests market by product type (CBC, HGB/HCT, BMP, BUN Creatinine, Electrolyte Testing, HbA1c, CMP, Liver Panel, Renal Panel and Lipid Panel), by end-user/application (Central Laboratories and Primary Clinics), and by geography (North America, South America, Europe, Asia-Pacific and MEA) along with country level break-up. This section of our report presents a realistic picture of the Global Diagnostic Tests industry. Investors and Players can easily understand the inherent opportunities and challenges for their products in geographical region of interest. For instance, while the holds majority of market share of the Diagnostic Tests market

Analyst at AMA have segmented the market study of Global Diagnostic Tests market by Type, Application and Region.

Influencing Trend:
The Rising Awareness of the Necessity of Regular Body Profiling Among Healthcare Professionals and Patients, Growing Awareness about Laboratory Tests in Clinics among Patients and Physicians and Increasing Awareness about the Prevalence of Cardiovascular Disorders and Diabetes

Market Growth Drivers:
Increasing Prevalence of Chronic Diseases and Rising Awareness among Health-Conscious Population, Increasing Geriatric Population and Growing Investments in Diagnosing Target Diseases Such As Cardiovascular Disorders, Tuberculosis, and Diabetes

Challenges:
Inadequate Reimbursement and Rising Healthcare Costs

Restraints:
Shortage of Reagents

Opportunities:
Growing Penetration of Advanced Diagnostic Techniques and Positive Economic Growth, And Increasing Avenues of Scientific Research

Market Developments Activities:
In February 2024, Diagnostic and preventive healthcare service provider Thyrocare announced on Monday the acquisition of a 100 per cent stake in Chennai-based Think Health Diagnostics for an undisclosed sum. The share purchase agreement was finalised on February 1, 2024, marking Thyrocare's entry into the domain of ECG services at home.
In August 2023, The service has been developed and launched by Newfoundland, a specialist in at-home diagnostic tests and will allow users to book an appointment with a registered GP via Doctor Call, a specialist in virtual and at-home GP appointments.



The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to avail of competitive advantage through combined collaborations.

Key Target Audience
Providers of Diagnostic Tests, Commercial Research & Development (R&D) Institutions, Government Organizations, Research Organizations and Healthcare Industry

Report Objectives / Segmentation Covered

By Type
  • CBC
  • HGB/HCT
  • BMP
  • BUN Creatinine
  • Electrolyte Testing
  • HbA1c
  • CMP
  • Liver Panel
  • Renal Panel
  • Lipid Panel
By Application
  • Central Laboratories
  • Primary Clinics
By Disease Type
  • Hepatitis
  • HIV
  • HAI
  • HPV
  • TB
  • Influenza

By Technology
  • Immunodiagnostics
  • PCR
  • NGS

By Service Type
  • Assay
  • Kit & Reagent
  • Instruments

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Chronic Diseases and Rising Awareness among Health-Conscious Population
      • 3.2.2. Increasing Geriatric Population
      • 3.2.3. Growing Investments in Diagnosing Target Diseases Such As Cardiovascular Disorders, Tuberculosis, and Diabetes
    • 3.3. Market Challenges
      • 3.3.1. Inadequate Reimbursement and Rising Healthcare Costs
    • 3.4. Market Trends
      • 3.4.1. The Rising Awareness of the Necessity of Regular Body Profiling Among Healthcare Professionals and Patients
      • 3.4.2. Growing Awareness about Laboratory Tests in Clinics among Patients and Physicians
      • 3.4.3. Increasing Awareness about the Prevalence of Cardiovascular Disorders and Diabetes
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Diagnostic Tests, by Type, Application, Disease Type, Technology, Service Type and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Diagnostic Tests (Value)
      • 5.2.1. Global Diagnostic Tests by: Type (Value)
        • 5.2.1.1. CBC
        • 5.2.1.2. HGB/HCT
        • 5.2.1.3. BMP
        • 5.2.1.4. BUN Creatinine
        • 5.2.1.5. Electrolyte Testing
        • 5.2.1.6. HbA1c
        • 5.2.1.7. CMP
        • 5.2.1.8. Liver Panel
        • 5.2.1.9. Renal Panel
        • 5.2.1.10. Lipid Panel
      • 5.2.2. Global Diagnostic Tests by: Application (Value)
        • 5.2.2.1. Central Laboratories
        • 5.2.2.2. Primary Clinics
      • 5.2.3. Global Diagnostic Tests by: Disease Type (Value)
        • 5.2.3.1. Hepatitis
        • 5.2.3.2. HIV
        • 5.2.3.3. HAI
        • 5.2.3.4. HPV
        • 5.2.3.5. TB
        • 5.2.3.6. Influenza
      • 5.2.4. Global Diagnostic Tests by: Technology (Value)
        • 5.2.4.1. Immunodiagnostics
        • 5.2.4.2. PCR
        • 5.2.4.3. NGS
      • 5.2.5. Global Diagnostic Tests by: Service Type (Value)
        • 5.2.5.1. Assay
        • 5.2.5.2. Kit & Reagent
        • 5.2.5.3. Instruments
      • 5.2.6. Global Diagnostic Tests Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Diagnostic Tests: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. ARUP Laboratories (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. OPKO Health, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bioscientia Institut für Medizinische Diagnostik GmbH (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Charles River Laboratories (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Fresenius Medical Care (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. QIAGEN (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. NeoGenomics Laboratories, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Genoptix, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Healthscope Ltd. (Australia)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Labco (South Africa)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Diagnostic Tests Sale, by Type, Application, Disease Type, Technology, Service Type and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Diagnostic Tests (Value)
      • 7.2.1. Global Diagnostic Tests by: Type (Value)
        • 7.2.1.1. CBC
        • 7.2.1.2. HGB/HCT
        • 7.2.1.3. BMP
        • 7.2.1.4. BUN Creatinine
        • 7.2.1.5. Electrolyte Testing
        • 7.2.1.6. HbA1c
        • 7.2.1.7. CMP
        • 7.2.1.8. Liver Panel
        • 7.2.1.9. Renal Panel
        • 7.2.1.10. Lipid Panel
      • 7.2.2. Global Diagnostic Tests by: Application (Value)
        • 7.2.2.1. Central Laboratories
        • 7.2.2.2. Primary Clinics
      • 7.2.3. Global Diagnostic Tests by: Disease Type (Value)
        • 7.2.3.1. Hepatitis
        • 7.2.3.2. HIV
        • 7.2.3.3. HAI
        • 7.2.3.4. HPV
        • 7.2.3.5. TB
        • 7.2.3.6. Influenza
      • 7.2.4. Global Diagnostic Tests by: Technology (Value)
        • 7.2.4.1. Immunodiagnostics
        • 7.2.4.2. PCR
        • 7.2.4.3. NGS
      • 7.2.5. Global Diagnostic Tests by: Service Type (Value)
        • 7.2.5.1. Assay
        • 7.2.5.2. Kit & Reagent
        • 7.2.5.3. Instruments
      • 7.2.6. Global Diagnostic Tests Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Diagnostic Tests: by Type(USD Million)
  • Table 2. Diagnostic Tests CBC , by Region USD Million (2018-2023)
  • Table 3. Diagnostic Tests HGB/HCT , by Region USD Million (2018-2023)
  • Table 4. Diagnostic Tests BMP , by Region USD Million (2018-2023)
  • Table 5. Diagnostic Tests BUN Creatinine , by Region USD Million (2018-2023)
  • Table 6. Diagnostic Tests Electrolyte Testing , by Region USD Million (2018-2023)
  • Table 7. Diagnostic Tests HbA1c , by Region USD Million (2018-2023)
  • Table 8. Diagnostic Tests CMP , by Region USD Million (2018-2023)
  • Table 9. Diagnostic Tests Liver Panel , by Region USD Million (2018-2023)
  • Table 10. Diagnostic Tests Renal Panel , by Region USD Million (2018-2023)
  • Table 11. Diagnostic Tests Lipid Panel , by Region USD Million (2018-2023)
  • Table 12. Diagnostic Tests: by Application(USD Million)
  • Table 13. Diagnostic Tests Central Laboratories , by Region USD Million (2018-2023)
  • Table 14. Diagnostic Tests Primary Clinics , by Region USD Million (2018-2023)
  • Table 15. Diagnostic Tests: by Disease Type(USD Million)
  • Table 16. Diagnostic Tests Hepatitis , by Region USD Million (2018-2023)
  • Table 17. Diagnostic Tests HIV , by Region USD Million (2018-2023)
  • Table 18. Diagnostic Tests HAI , by Region USD Million (2018-2023)
  • Table 19. Diagnostic Tests HPV , by Region USD Million (2018-2023)
  • Table 20. Diagnostic Tests TB , by Region USD Million (2018-2023)
  • Table 21. Diagnostic Tests Influenza , by Region USD Million (2018-2023)
  • Table 22. Diagnostic Tests: by Technology(USD Million)
  • Table 23. Diagnostic Tests Immunodiagnostics , by Region USD Million (2018-2023)
  • Table 24. Diagnostic Tests PCR , by Region USD Million (2018-2023)
  • Table 25. Diagnostic Tests NGS , by Region USD Million (2018-2023)
  • Table 26. Diagnostic Tests: by Service Type(USD Million)
  • Table 27. Diagnostic Tests Assay , by Region USD Million (2018-2023)
  • Table 28. Diagnostic Tests Kit & Reagent , by Region USD Million (2018-2023)
  • Table 29. Diagnostic Tests Instruments , by Region USD Million (2018-2023)
  • Table 30. South America Diagnostic Tests, by Country USD Million (2018-2023)
  • Table 31. South America Diagnostic Tests, by Type USD Million (2018-2023)
  • Table 32. South America Diagnostic Tests, by Application USD Million (2018-2023)
  • Table 33. South America Diagnostic Tests, by Disease Type USD Million (2018-2023)
  • Table 34. South America Diagnostic Tests, by Technology USD Million (2018-2023)
  • Table 35. South America Diagnostic Tests, by Service Type USD Million (2018-2023)
  • Table 36. Brazil Diagnostic Tests, by Type USD Million (2018-2023)
  • Table 37. Brazil Diagnostic Tests, by Application USD Million (2018-2023)
  • Table 38. Brazil Diagnostic Tests, by Disease Type USD Million (2018-2023)
  • Table 39. Brazil Diagnostic Tests, by Technology USD Million (2018-2023)
  • Table 40. Brazil Diagnostic Tests, by Service Type USD Million (2018-2023)
  • Table 41. Argentina Diagnostic Tests, by Type USD Million (2018-2023)
  • Table 42. Argentina Diagnostic Tests, by Application USD Million (2018-2023)
  • Table 43. Argentina Diagnostic Tests, by Disease Type USD Million (2018-2023)
  • Table 44. Argentina Diagnostic Tests, by Technology USD Million (2018-2023)
  • Table 45. Argentina Diagnostic Tests, by Service Type USD Million (2018-2023)
  • Table 46. Rest of South America Diagnostic Tests, by Type USD Million (2018-2023)
  • Table 47. Rest of South America Diagnostic Tests, by Application USD Million (2018-2023)
  • Table 48. Rest of South America Diagnostic Tests, by Disease Type USD Million (2018-2023)
  • Table 49. Rest of South America Diagnostic Tests, by Technology USD Million (2018-2023)
  • Table 50. Rest of South America Diagnostic Tests, by Service Type USD Million (2018-2023)
  • Table 51. Asia Pacific Diagnostic Tests, by Country USD Million (2018-2023)
  • Table 52. Asia Pacific Diagnostic Tests, by Type USD Million (2018-2023)
  • Table 53. Asia Pacific Diagnostic Tests, by Application USD Million (2018-2023)
  • Table 54. Asia Pacific Diagnostic Tests, by Disease Type USD Million (2018-2023)
  • Table 55. Asia Pacific Diagnostic Tests, by Technology USD Million (2018-2023)
  • Table 56. Asia Pacific Diagnostic Tests, by Service Type USD Million (2018-2023)
  • Table 57. China Diagnostic Tests, by Type USD Million (2018-2023)
  • Table 58. China Diagnostic Tests, by Application USD Million (2018-2023)
  • Table 59. China Diagnostic Tests, by Disease Type USD Million (2018-2023)
  • Table 60. China Diagnostic Tests, by Technology USD Million (2018-2023)
  • Table 61. China Diagnostic Tests, by Service Type USD Million (2018-2023)
  • Table 62. Japan Diagnostic Tests, by Type USD Million (2018-2023)
  • Table 63. Japan Diagnostic Tests, by Application USD Million (2018-2023)
  • Table 64. Japan Diagnostic Tests, by Disease Type USD Million (2018-2023)
  • Table 65. Japan Diagnostic Tests, by Technology USD Million (2018-2023)
  • Table 66. Japan Diagnostic Tests, by Service Type USD Million (2018-2023)
  • Table 67. India Diagnostic Tests, by Type USD Million (2018-2023)
  • Table 68. India Diagnostic Tests, by Application USD Million (2018-2023)
  • Table 69. India Diagnostic Tests, by Disease Type USD Million (2018-2023)
  • Table 70. India Diagnostic Tests, by Technology USD Million (2018-2023)
  • Table 71. India Diagnostic Tests, by Service Type USD Million (2018-2023)
  • Table 72. South Korea Diagnostic Tests, by Type USD Million (2018-2023)
  • Table 73. South Korea Diagnostic Tests, by Application USD Million (2018-2023)
  • Table 74. South Korea Diagnostic Tests, by Disease Type USD Million (2018-2023)
  • Table 75. South Korea Diagnostic Tests, by Technology USD Million (2018-2023)
  • Table 76. South Korea Diagnostic Tests, by Service Type USD Million (2018-2023)
  • Table 77. Taiwan Diagnostic Tests, by Type USD Million (2018-2023)
  • Table 78. Taiwan Diagnostic Tests, by Application USD Million (2018-2023)
  • Table 79. Taiwan Diagnostic Tests, by Disease Type USD Million (2018-2023)
  • Table 80. Taiwan Diagnostic Tests, by Technology USD Million (2018-2023)
  • Table 81. Taiwan Diagnostic Tests, by Service Type USD Million (2018-2023)
  • Table 82. Australia Diagnostic Tests, by Type USD Million (2018-2023)
  • Table 83. Australia Diagnostic Tests, by Application USD Million (2018-2023)
  • Table 84. Australia Diagnostic Tests, by Disease Type USD Million (2018-2023)
  • Table 85. Australia Diagnostic Tests, by Technology USD Million (2018-2023)
  • Table 86. Australia Diagnostic Tests, by Service Type USD Million (2018-2023)
  • Table 87. Rest of Asia-Pacific Diagnostic Tests, by Type USD Million (2018-2023)
  • Table 88. Rest of Asia-Pacific Diagnostic Tests, by Application USD Million (2018-2023)
  • Table 89. Rest of Asia-Pacific Diagnostic Tests, by Disease Type USD Million (2018-2023)
  • Table 90. Rest of Asia-Pacific Diagnostic Tests, by Technology USD Million (2018-2023)
  • Table 91. Rest of Asia-Pacific Diagnostic Tests, by Service Type USD Million (2018-2023)
  • Table 92. Europe Diagnostic Tests, by Country USD Million (2018-2023)
  • Table 93. Europe Diagnostic Tests, by Type USD Million (2018-2023)
  • Table 94. Europe Diagnostic Tests, by Application USD Million (2018-2023)
  • Table 95. Europe Diagnostic Tests, by Disease Type USD Million (2018-2023)
  • Table 96. Europe Diagnostic Tests, by Technology USD Million (2018-2023)
  • Table 97. Europe Diagnostic Tests, by Service Type USD Million (2018-2023)
  • Table 98. Germany Diagnostic Tests, by Type USD Million (2018-2023)
  • Table 99. Germany Diagnostic Tests, by Application USD Million (2018-2023)
  • Table 100. Germany Diagnostic Tests, by Disease Type USD Million (2018-2023)
  • Table 101. Germany Diagnostic Tests, by Technology USD Million (2018-2023)
  • Table 102. Germany Diagnostic Tests, by Service Type USD Million (2018-2023)
  • Table 103. France Diagnostic Tests, by Type USD Million (2018-2023)
  • Table 104. France Diagnostic Tests, by Application USD Million (2018-2023)
  • Table 105. France Diagnostic Tests, by Disease Type USD Million (2018-2023)
  • Table 106. France Diagnostic Tests, by Technology USD Million (2018-2023)
  • Table 107. France Diagnostic Tests, by Service Type USD Million (2018-2023)
  • Table 108. Italy Diagnostic Tests, by Type USD Million (2018-2023)
  • Table 109. Italy Diagnostic Tests, by Application USD Million (2018-2023)
  • Table 110. Italy Diagnostic Tests, by Disease Type USD Million (2018-2023)
  • Table 111. Italy Diagnostic Tests, by Technology USD Million (2018-2023)
  • Table 112. Italy Diagnostic Tests, by Service Type USD Million (2018-2023)
  • Table 113. United Kingdom Diagnostic Tests, by Type USD Million (2018-2023)
  • Table 114. United Kingdom Diagnostic Tests, by Application USD Million (2018-2023)
  • Table 115. United Kingdom Diagnostic Tests, by Disease Type USD Million (2018-2023)
  • Table 116. United Kingdom Diagnostic Tests, by Technology USD Million (2018-2023)
  • Table 117. United Kingdom Diagnostic Tests, by Service Type USD Million (2018-2023)
  • Table 118. Netherlands Diagnostic Tests, by Type USD Million (2018-2023)
  • Table 119. Netherlands Diagnostic Tests, by Application USD Million (2018-2023)
  • Table 120. Netherlands Diagnostic Tests, by Disease Type USD Million (2018-2023)
  • Table 121. Netherlands Diagnostic Tests, by Technology USD Million (2018-2023)
  • Table 122. Netherlands Diagnostic Tests, by Service Type USD Million (2018-2023)
  • Table 123. Rest of Europe Diagnostic Tests, by Type USD Million (2018-2023)
  • Table 124. Rest of Europe Diagnostic Tests, by Application USD Million (2018-2023)
  • Table 125. Rest of Europe Diagnostic Tests, by Disease Type USD Million (2018-2023)
  • Table 126. Rest of Europe Diagnostic Tests, by Technology USD Million (2018-2023)
  • Table 127. Rest of Europe Diagnostic Tests, by Service Type USD Million (2018-2023)
  • Table 128. MEA Diagnostic Tests, by Country USD Million (2018-2023)
  • Table 129. MEA Diagnostic Tests, by Type USD Million (2018-2023)
  • Table 130. MEA Diagnostic Tests, by Application USD Million (2018-2023)
  • Table 131. MEA Diagnostic Tests, by Disease Type USD Million (2018-2023)
  • Table 132. MEA Diagnostic Tests, by Technology USD Million (2018-2023)
  • Table 133. MEA Diagnostic Tests, by Service Type USD Million (2018-2023)
  • Table 134. Middle East Diagnostic Tests, by Type USD Million (2018-2023)
  • Table 135. Middle East Diagnostic Tests, by Application USD Million (2018-2023)
  • Table 136. Middle East Diagnostic Tests, by Disease Type USD Million (2018-2023)
  • Table 137. Middle East Diagnostic Tests, by Technology USD Million (2018-2023)
  • Table 138. Middle East Diagnostic Tests, by Service Type USD Million (2018-2023)
  • Table 139. Africa Diagnostic Tests, by Type USD Million (2018-2023)
  • Table 140. Africa Diagnostic Tests, by Application USD Million (2018-2023)
  • Table 141. Africa Diagnostic Tests, by Disease Type USD Million (2018-2023)
  • Table 142. Africa Diagnostic Tests, by Technology USD Million (2018-2023)
  • Table 143. Africa Diagnostic Tests, by Service Type USD Million (2018-2023)
  • Table 144. North America Diagnostic Tests, by Country USD Million (2018-2023)
  • Table 145. North America Diagnostic Tests, by Type USD Million (2018-2023)
  • Table 146. North America Diagnostic Tests, by Application USD Million (2018-2023)
  • Table 147. North America Diagnostic Tests, by Disease Type USD Million (2018-2023)
  • Table 148. North America Diagnostic Tests, by Technology USD Million (2018-2023)
  • Table 149. North America Diagnostic Tests, by Service Type USD Million (2018-2023)
  • Table 150. United States Diagnostic Tests, by Type USD Million (2018-2023)
  • Table 151. United States Diagnostic Tests, by Application USD Million (2018-2023)
  • Table 152. United States Diagnostic Tests, by Disease Type USD Million (2018-2023)
  • Table 153. United States Diagnostic Tests, by Technology USD Million (2018-2023)
  • Table 154. United States Diagnostic Tests, by Service Type USD Million (2018-2023)
  • Table 155. Canada Diagnostic Tests, by Type USD Million (2018-2023)
  • Table 156. Canada Diagnostic Tests, by Application USD Million (2018-2023)
  • Table 157. Canada Diagnostic Tests, by Disease Type USD Million (2018-2023)
  • Table 158. Canada Diagnostic Tests, by Technology USD Million (2018-2023)
  • Table 159. Canada Diagnostic Tests, by Service Type USD Million (2018-2023)
  • Table 160. Mexico Diagnostic Tests, by Type USD Million (2018-2023)
  • Table 161. Mexico Diagnostic Tests, by Application USD Million (2018-2023)
  • Table 162. Mexico Diagnostic Tests, by Disease Type USD Million (2018-2023)
  • Table 163. Mexico Diagnostic Tests, by Technology USD Million (2018-2023)
  • Table 164. Mexico Diagnostic Tests, by Service Type USD Million (2018-2023)
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Company Basic Information, Sales Area and Its Competitors
  • Table 171. Company Basic Information, Sales Area and Its Competitors
  • Table 172. Company Basic Information, Sales Area and Its Competitors
  • Table 173. Company Basic Information, Sales Area and Its Competitors
  • Table 174. Company Basic Information, Sales Area and Its Competitors
  • Table 175. Company Basic Information, Sales Area and Its Competitors
  • Table 176. Diagnostic Tests: by Type(USD Million)
  • Table 177. Diagnostic Tests CBC , by Region USD Million (2025-2030)
  • Table 178. Diagnostic Tests HGB/HCT , by Region USD Million (2025-2030)
  • Table 179. Diagnostic Tests BMP , by Region USD Million (2025-2030)
  • Table 180. Diagnostic Tests BUN Creatinine , by Region USD Million (2025-2030)
  • Table 181. Diagnostic Tests Electrolyte Testing , by Region USD Million (2025-2030)
  • Table 182. Diagnostic Tests HbA1c , by Region USD Million (2025-2030)
  • Table 183. Diagnostic Tests CMP , by Region USD Million (2025-2030)
  • Table 184. Diagnostic Tests Liver Panel , by Region USD Million (2025-2030)
  • Table 185. Diagnostic Tests Renal Panel , by Region USD Million (2025-2030)
  • Table 186. Diagnostic Tests Lipid Panel , by Region USD Million (2025-2030)
  • Table 187. Diagnostic Tests: by Application(USD Million)
  • Table 188. Diagnostic Tests Central Laboratories , by Region USD Million (2025-2030)
  • Table 189. Diagnostic Tests Primary Clinics , by Region USD Million (2025-2030)
  • Table 190. Diagnostic Tests: by Disease Type(USD Million)
  • Table 191. Diagnostic Tests Hepatitis , by Region USD Million (2025-2030)
  • Table 192. Diagnostic Tests HIV , by Region USD Million (2025-2030)
  • Table 193. Diagnostic Tests HAI , by Region USD Million (2025-2030)
  • Table 194. Diagnostic Tests HPV , by Region USD Million (2025-2030)
  • Table 195. Diagnostic Tests TB , by Region USD Million (2025-2030)
  • Table 196. Diagnostic Tests Influenza , by Region USD Million (2025-2030)
  • Table 197. Diagnostic Tests: by Technology(USD Million)
  • Table 198. Diagnostic Tests Immunodiagnostics , by Region USD Million (2025-2030)
  • Table 199. Diagnostic Tests PCR , by Region USD Million (2025-2030)
  • Table 200. Diagnostic Tests NGS , by Region USD Million (2025-2030)
  • Table 201. Diagnostic Tests: by Service Type(USD Million)
  • Table 202. Diagnostic Tests Assay , by Region USD Million (2025-2030)
  • Table 203. Diagnostic Tests Kit & Reagent , by Region USD Million (2025-2030)
  • Table 204. Diagnostic Tests Instruments , by Region USD Million (2025-2030)
  • Table 205. South America Diagnostic Tests, by Country USD Million (2025-2030)
  • Table 206. South America Diagnostic Tests, by Type USD Million (2025-2030)
  • Table 207. South America Diagnostic Tests, by Application USD Million (2025-2030)
  • Table 208. South America Diagnostic Tests, by Disease Type USD Million (2025-2030)
  • Table 209. South America Diagnostic Tests, by Technology USD Million (2025-2030)
  • Table 210. South America Diagnostic Tests, by Service Type USD Million (2025-2030)
  • Table 211. Brazil Diagnostic Tests, by Type USD Million (2025-2030)
  • Table 212. Brazil Diagnostic Tests, by Application USD Million (2025-2030)
  • Table 213. Brazil Diagnostic Tests, by Disease Type USD Million (2025-2030)
  • Table 214. Brazil Diagnostic Tests, by Technology USD Million (2025-2030)
  • Table 215. Brazil Diagnostic Tests, by Service Type USD Million (2025-2030)
  • Table 216. Argentina Diagnostic Tests, by Type USD Million (2025-2030)
  • Table 217. Argentina Diagnostic Tests, by Application USD Million (2025-2030)
  • Table 218. Argentina Diagnostic Tests, by Disease Type USD Million (2025-2030)
  • Table 219. Argentina Diagnostic Tests, by Technology USD Million (2025-2030)
  • Table 220. Argentina Diagnostic Tests, by Service Type USD Million (2025-2030)
  • Table 221. Rest of South America Diagnostic Tests, by Type USD Million (2025-2030)
  • Table 222. Rest of South America Diagnostic Tests, by Application USD Million (2025-2030)
  • Table 223. Rest of South America Diagnostic Tests, by Disease Type USD Million (2025-2030)
  • Table 224. Rest of South America Diagnostic Tests, by Technology USD Million (2025-2030)
  • Table 225. Rest of South America Diagnostic Tests, by Service Type USD Million (2025-2030)
  • Table 226. Asia Pacific Diagnostic Tests, by Country USD Million (2025-2030)
  • Table 227. Asia Pacific Diagnostic Tests, by Type USD Million (2025-2030)
  • Table 228. Asia Pacific Diagnostic Tests, by Application USD Million (2025-2030)
  • Table 229. Asia Pacific Diagnostic Tests, by Disease Type USD Million (2025-2030)
  • Table 230. Asia Pacific Diagnostic Tests, by Technology USD Million (2025-2030)
  • Table 231. Asia Pacific Diagnostic Tests, by Service Type USD Million (2025-2030)
  • Table 232. China Diagnostic Tests, by Type USD Million (2025-2030)
  • Table 233. China Diagnostic Tests, by Application USD Million (2025-2030)
  • Table 234. China Diagnostic Tests, by Disease Type USD Million (2025-2030)
  • Table 235. China Diagnostic Tests, by Technology USD Million (2025-2030)
  • Table 236. China Diagnostic Tests, by Service Type USD Million (2025-2030)
  • Table 237. Japan Diagnostic Tests, by Type USD Million (2025-2030)
  • Table 238. Japan Diagnostic Tests, by Application USD Million (2025-2030)
  • Table 239. Japan Diagnostic Tests, by Disease Type USD Million (2025-2030)
  • Table 240. Japan Diagnostic Tests, by Technology USD Million (2025-2030)
  • Table 241. Japan Diagnostic Tests, by Service Type USD Million (2025-2030)
  • Table 242. India Diagnostic Tests, by Type USD Million (2025-2030)
  • Table 243. India Diagnostic Tests, by Application USD Million (2025-2030)
  • Table 244. India Diagnostic Tests, by Disease Type USD Million (2025-2030)
  • Table 245. India Diagnostic Tests, by Technology USD Million (2025-2030)
  • Table 246. India Diagnostic Tests, by Service Type USD Million (2025-2030)
  • Table 247. South Korea Diagnostic Tests, by Type USD Million (2025-2030)
  • Table 248. South Korea Diagnostic Tests, by Application USD Million (2025-2030)
  • Table 249. South Korea Diagnostic Tests, by Disease Type USD Million (2025-2030)
  • Table 250. South Korea Diagnostic Tests, by Technology USD Million (2025-2030)
  • Table 251. South Korea Diagnostic Tests, by Service Type USD Million (2025-2030)
  • Table 252. Taiwan Diagnostic Tests, by Type USD Million (2025-2030)
  • Table 253. Taiwan Diagnostic Tests, by Application USD Million (2025-2030)
  • Table 254. Taiwan Diagnostic Tests, by Disease Type USD Million (2025-2030)
  • Table 255. Taiwan Diagnostic Tests, by Technology USD Million (2025-2030)
  • Table 256. Taiwan Diagnostic Tests, by Service Type USD Million (2025-2030)
  • Table 257. Australia Diagnostic Tests, by Type USD Million (2025-2030)
  • Table 258. Australia Diagnostic Tests, by Application USD Million (2025-2030)
  • Table 259. Australia Diagnostic Tests, by Disease Type USD Million (2025-2030)
  • Table 260. Australia Diagnostic Tests, by Technology USD Million (2025-2030)
  • Table 261. Australia Diagnostic Tests, by Service Type USD Million (2025-2030)
  • Table 262. Rest of Asia-Pacific Diagnostic Tests, by Type USD Million (2025-2030)
  • Table 263. Rest of Asia-Pacific Diagnostic Tests, by Application USD Million (2025-2030)
  • Table 264. Rest of Asia-Pacific Diagnostic Tests, by Disease Type USD Million (2025-2030)
  • Table 265. Rest of Asia-Pacific Diagnostic Tests, by Technology USD Million (2025-2030)
  • Table 266. Rest of Asia-Pacific Diagnostic Tests, by Service Type USD Million (2025-2030)
  • Table 267. Europe Diagnostic Tests, by Country USD Million (2025-2030)
  • Table 268. Europe Diagnostic Tests, by Type USD Million (2025-2030)
  • Table 269. Europe Diagnostic Tests, by Application USD Million (2025-2030)
  • Table 270. Europe Diagnostic Tests, by Disease Type USD Million (2025-2030)
  • Table 271. Europe Diagnostic Tests, by Technology USD Million (2025-2030)
  • Table 272. Europe Diagnostic Tests, by Service Type USD Million (2025-2030)
  • Table 273. Germany Diagnostic Tests, by Type USD Million (2025-2030)
  • Table 274. Germany Diagnostic Tests, by Application USD Million (2025-2030)
  • Table 275. Germany Diagnostic Tests, by Disease Type USD Million (2025-2030)
  • Table 276. Germany Diagnostic Tests, by Technology USD Million (2025-2030)
  • Table 277. Germany Diagnostic Tests, by Service Type USD Million (2025-2030)
  • Table 278. France Diagnostic Tests, by Type USD Million (2025-2030)
  • Table 279. France Diagnostic Tests, by Application USD Million (2025-2030)
  • Table 280. France Diagnostic Tests, by Disease Type USD Million (2025-2030)
  • Table 281. France Diagnostic Tests, by Technology USD Million (2025-2030)
  • Table 282. France Diagnostic Tests, by Service Type USD Million (2025-2030)
  • Table 283. Italy Diagnostic Tests, by Type USD Million (2025-2030)
  • Table 284. Italy Diagnostic Tests, by Application USD Million (2025-2030)
  • Table 285. Italy Diagnostic Tests, by Disease Type USD Million (2025-2030)
  • Table 286. Italy Diagnostic Tests, by Technology USD Million (2025-2030)
  • Table 287. Italy Diagnostic Tests, by Service Type USD Million (2025-2030)
  • Table 288. United Kingdom Diagnostic Tests, by Type USD Million (2025-2030)
  • Table 289. United Kingdom Diagnostic Tests, by Application USD Million (2025-2030)
  • Table 290. United Kingdom Diagnostic Tests, by Disease Type USD Million (2025-2030)
  • Table 291. United Kingdom Diagnostic Tests, by Technology USD Million (2025-2030)
  • Table 292. United Kingdom Diagnostic Tests, by Service Type USD Million (2025-2030)
  • Table 293. Netherlands Diagnostic Tests, by Type USD Million (2025-2030)
  • Table 294. Netherlands Diagnostic Tests, by Application USD Million (2025-2030)
  • Table 295. Netherlands Diagnostic Tests, by Disease Type USD Million (2025-2030)
  • Table 296. Netherlands Diagnostic Tests, by Technology USD Million (2025-2030)
  • Table 297. Netherlands Diagnostic Tests, by Service Type USD Million (2025-2030)
  • Table 298. Rest of Europe Diagnostic Tests, by Type USD Million (2025-2030)
  • Table 299. Rest of Europe Diagnostic Tests, by Application USD Million (2025-2030)
  • Table 300. Rest of Europe Diagnostic Tests, by Disease Type USD Million (2025-2030)
  • Table 301. Rest of Europe Diagnostic Tests, by Technology USD Million (2025-2030)
  • Table 302. Rest of Europe Diagnostic Tests, by Service Type USD Million (2025-2030)
  • Table 303. MEA Diagnostic Tests, by Country USD Million (2025-2030)
  • Table 304. MEA Diagnostic Tests, by Type USD Million (2025-2030)
  • Table 305. MEA Diagnostic Tests, by Application USD Million (2025-2030)
  • Table 306. MEA Diagnostic Tests, by Disease Type USD Million (2025-2030)
  • Table 307. MEA Diagnostic Tests, by Technology USD Million (2025-2030)
  • Table 308. MEA Diagnostic Tests, by Service Type USD Million (2025-2030)
  • Table 309. Middle East Diagnostic Tests, by Type USD Million (2025-2030)
  • Table 310. Middle East Diagnostic Tests, by Application USD Million (2025-2030)
  • Table 311. Middle East Diagnostic Tests, by Disease Type USD Million (2025-2030)
  • Table 312. Middle East Diagnostic Tests, by Technology USD Million (2025-2030)
  • Table 313. Middle East Diagnostic Tests, by Service Type USD Million (2025-2030)
  • Table 314. Africa Diagnostic Tests, by Type USD Million (2025-2030)
  • Table 315. Africa Diagnostic Tests, by Application USD Million (2025-2030)
  • Table 316. Africa Diagnostic Tests, by Disease Type USD Million (2025-2030)
  • Table 317. Africa Diagnostic Tests, by Technology USD Million (2025-2030)
  • Table 318. Africa Diagnostic Tests, by Service Type USD Million (2025-2030)
  • Table 319. North America Diagnostic Tests, by Country USD Million (2025-2030)
  • Table 320. North America Diagnostic Tests, by Type USD Million (2025-2030)
  • Table 321. North America Diagnostic Tests, by Application USD Million (2025-2030)
  • Table 322. North America Diagnostic Tests, by Disease Type USD Million (2025-2030)
  • Table 323. North America Diagnostic Tests, by Technology USD Million (2025-2030)
  • Table 324. North America Diagnostic Tests, by Service Type USD Million (2025-2030)
  • Table 325. United States Diagnostic Tests, by Type USD Million (2025-2030)
  • Table 326. United States Diagnostic Tests, by Application USD Million (2025-2030)
  • Table 327. United States Diagnostic Tests, by Disease Type USD Million (2025-2030)
  • Table 328. United States Diagnostic Tests, by Technology USD Million (2025-2030)
  • Table 329. United States Diagnostic Tests, by Service Type USD Million (2025-2030)
  • Table 330. Canada Diagnostic Tests, by Type USD Million (2025-2030)
  • Table 331. Canada Diagnostic Tests, by Application USD Million (2025-2030)
  • Table 332. Canada Diagnostic Tests, by Disease Type USD Million (2025-2030)
  • Table 333. Canada Diagnostic Tests, by Technology USD Million (2025-2030)
  • Table 334. Canada Diagnostic Tests, by Service Type USD Million (2025-2030)
  • Table 335. Mexico Diagnostic Tests, by Type USD Million (2025-2030)
  • Table 336. Mexico Diagnostic Tests, by Application USD Million (2025-2030)
  • Table 337. Mexico Diagnostic Tests, by Disease Type USD Million (2025-2030)
  • Table 338. Mexico Diagnostic Tests, by Technology USD Million (2025-2030)
  • Table 339. Mexico Diagnostic Tests, by Service Type USD Million (2025-2030)
  • Table 340. Research Programs/Design for This Report
  • Table 341. Key Data Information from Secondary Sources
  • Table 342. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Diagnostic Tests: by Type USD Million (2018-2023)
  • Figure 5. Global Diagnostic Tests: by Application USD Million (2018-2023)
  • Figure 6. Global Diagnostic Tests: by Disease Type USD Million (2018-2023)
  • Figure 7. Global Diagnostic Tests: by Technology USD Million (2018-2023)
  • Figure 8. Global Diagnostic Tests: by Service Type USD Million (2018-2023)
  • Figure 9. South America Diagnostic Tests Share (%), by Country
  • Figure 10. Asia Pacific Diagnostic Tests Share (%), by Country
  • Figure 11. Europe Diagnostic Tests Share (%), by Country
  • Figure 12. MEA Diagnostic Tests Share (%), by Country
  • Figure 13. North America Diagnostic Tests Share (%), by Country
  • Figure 14. Global Diagnostic Tests share by Players 2023 (%)
  • Figure 15. Global Diagnostic Tests share by Players (Top 3) 2023(%)
  • Figure 16. Global Diagnostic Tests share by Players (Top 5) 2023(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 19. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 20. ARUP Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 21. ARUP Laboratories (United States) Revenue: by Geography 2023
  • Figure 22. OPKO Health, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. OPKO Health, Inc. (United States) Revenue: by Geography 2023
  • Figure 24. Bioscientia Institut für Medizinische Diagnostik GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 25. Bioscientia Institut für Medizinische Diagnostik GmbH (Germany) Revenue: by Geography 2023
  • Figure 26. Charles River Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 27. Charles River Laboratories (United States) Revenue: by Geography 2023
  • Figure 28. Fresenius Medical Care (Germany) Revenue, Net Income and Gross profit
  • Figure 29. Fresenius Medical Care (Germany) Revenue: by Geography 2023
  • Figure 30. QIAGEN (Germany) Revenue, Net Income and Gross profit
  • Figure 31. QIAGEN (Germany) Revenue: by Geography 2023
  • Figure 32. NeoGenomics Laboratories, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. NeoGenomics Laboratories, Inc. (United States) Revenue: by Geography 2023
  • Figure 34. Genoptix, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Genoptix, Inc. (United States) Revenue: by Geography 2023
  • Figure 36. Healthscope Ltd. (Australia) Revenue, Net Income and Gross profit
  • Figure 37. Healthscope Ltd. (Australia) Revenue: by Geography 2023
  • Figure 38. Labco (South Africa) Revenue, Net Income and Gross profit
  • Figure 39. Labco (South Africa) Revenue: by Geography 2023
  • Figure 40. Global Diagnostic Tests: by Type USD Million (2025-2030)
  • Figure 41. Global Diagnostic Tests: by Application USD Million (2025-2030)
  • Figure 42. Global Diagnostic Tests: by Disease Type USD Million (2025-2030)
  • Figure 43. Global Diagnostic Tests: by Technology USD Million (2025-2030)
  • Figure 44. Global Diagnostic Tests: by Service Type USD Million (2025-2030)
  • Figure 45. South America Diagnostic Tests Share (%), by Country
  • Figure 46. Asia Pacific Diagnostic Tests Share (%), by Country
  • Figure 47. Europe Diagnostic Tests Share (%), by Country
  • Figure 48. MEA Diagnostic Tests Share (%), by Country
  • Figure 49. North America Diagnostic Tests Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Abbott Laboratories (United States)
  • ARUP Laboratories (United States)
  • OPKO Health, Inc. (United States)
  • Bioscientia Institut für Medizinische Diagnostik GmbH (Germany)
  • Charles River Laboratories (United States)
  • Fresenius Medical Care (Germany)
  • QIAGEN (Germany)
  • NeoGenomics Laboratories, Inc. (United States)
  • Genoptix, Inc. (United States)
  • Healthscope Ltd. (Australia)
  • Labco (South Africa)
Additional players considered in the study are as follows:
Laboratory Corporation of America Holdings (LabCorp) (United States) , Quest Diagnostics (United States) , Siemens Healthcare Private Limited (India) , Tulip Diagnostics (P) Ltd. (India)
Select User Access Type

Key Highlights of Report


Mar 2024 224 Pages 73 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Diagnostic Tests Market Quantitative research analysis
Global Diagnostic Tests Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Due to pricing constraints we only profile limited players in the study that includes a mix list of leaders and emerging players, however for evaluation of market size the coverage includes 100+ players.
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2030
The Study can be customized to meet your requirements. Please connect with our representative, in case you wish to add or remove certain country or profiled players.
  • Inadequate Reimbursement and Rising Healthcare Costs

Know More About Global Diagnostic Tests Market Report?

Have a Query? Click Here

Other Related Reports

Opioid Withdrawal Treatment Comprehensive Study by Type (Outpatient Treatment, Inpatient Treatment), Drug Type (Nonsteroidal Anti-Inflammatory Drugs, Anti-Nausea Medications, Analgesics, Natural Slee...
$ 3650
Intelligent Care Support Comprehensive Study by Type (Rehabilitation of Auxiliary, Medical Support, Home Health Care, Other), Application (Home, Pension Agency, Hospital, Other) Players and Region - ...
$ 3800
Health Coaching Comprehensive Study by Coaching Type (Physical Activity, Nutrition & Eating Habits, Weight Management, Diabetes Prevention, Medication Adherence, Other), End User (Fitness Facilities ...
$ 3450
Targeted Protein Degradation Comprehensive Study by Type (Degronimids, IMiDs, PROTACs, SARDs, SERDs, Specific BET & DUB Inhibitors), Application (Healthcare), Therapeutic Area (Inflammatory Disorder...
$ 3650
Biosimilar Testing Service Comprehensive Study by Type (Pharmacokinetic Assay, Tiered Immunogenicity Testing, NAb Assays), Application (Pharmaceutical and Biopharmaceutical Companies, Contract resear...
$ 3800
Ophthalmic Data Management Systems Comprehensive Study by Deployment Mode (Cloud-Based, Web-Based), Disease Type (Glaucoma, Diabetic Retinopathy, Refractive Error, Age-Related Macular Degeneration, A...
$ 3750